Cartalax: Complete Research Profile — Khavinson Tripeptide Bioregulator for Cartilage, Chondrocyte, and Joint Tissue Research

Cartalax: Complete Research Profile — Khavinson Tripeptide Bioregulator for Cartilage, Chondrocyte, and Joint Tissue Research

Cartalax is a short synthetic tripeptide bioregulator (Ala-Glu-Asp; AED) developed within the Khavinson bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology — the same institution that produced Epitalon, Pinealon, and Thymalin. It represents the cartilage-targeting member of the Khavinson peptide family, selected based on sequence homology to peptide fragments found in type XI collagen and designed to modulate chondrocyte gene expression through proposed epigenetic mechanisms. In preclinical research, Cartalax has been associated with chondrocyte proliferation stimulation, collagen synthesis support, and markers consistent with cartilage tissue homeostasis — making it a distinct research tool for connective tissue biology.

For dosing, reconstitution, and protocol details, see our Cartalax (EDR Tripeptide) Dosage Protocol Guide: Khavinson Bioregulator for Cartilage and Chondrocyte Research 2026.

This profile is provided for Research Use Only (RUO). All content is for educational and scientific research purposes only.

---

Quick Reference

---

Structural Identity

Sequence: Ala-Glu-Asp (AED)

Molecular Weight: ~333 Da

Class: Khavinson short peptide bioregulator (tripeptide)

Source: Synthetic; originally isolated from cartilage tissue peptide fractions before chemical synthesis

Tissue Target: Articular cartilage, chondrocytes, connective tissue

CAS: Available through peptide supplier databases; verify by MW + sequence confirmation

Cartalax's sequence (Ala-Glu-Asp) bears structural homology to alpha-1 chain segments of type XI collagen, a fibrillar collagen important for regulating the diameter and organization of type II collagen fibrils in hyaline cartilage. The Khavinson group hypothesized that short peptides matching natural tissue sequences act as endogenous "biological cues" that can interact with chromatin and modulate gene expression in the corresponding tissue type — the proposed mechanism underlying the entire Khavinson bioregulator class.

The AED Tripeptide Sequence

The three amino acids in Cartalax each carry distinct properties:

• •Alanine (Ala, A): Small, non-polar amino acid; common in collagen α-chains (GXY repeat motifs); provides structural compactness to the peptide
• •Glutamic acid (Glu, E): Negatively charged at physiological pH; key contributor to interactions with positively charged histone residues in the proposed DNA-binding mechanism
• •Aspartic acid (Asp, D): Negatively charged at physiological pH; similar electrochemical properties to Glu but shorter side chain; contributes to DNA phosphate backbone interactions in molecular models

The net charge of AED at physiological pH is approximately -2, suggesting electrostatic interactions with histones or other cationic proteins could be relevant to its proposed mechanism.

---

The Khavinson Bioregulator Framework

Understanding Cartalax requires context about the broader Khavinson peptide research tradition:

Historical background: Beginning in the 1970s, Vladimir Khavinson and colleagues at the Institute of Bioregulation developed a systematic approach to tissue-specific short peptide identification. Peptide extracts from specific organs and tissues were fractionated and the most biologically active short sequences identified, synthesized, and tested in aging and disease models. This produced a family of 2–5 amino acid peptides including:

The Khavinson Bioregulator Hypothesis:

The unifying hypothesis is that these short peptides — derived from tissue-specific protein sequences — can "reset" age-related gene expression changes in their corresponding target tissues. The proposed mechanism involves:

1. Short peptide penetrates cell nucleus (small enough for passive nuclear entry)

2. Peptide binds directly to DNA in promoter regions of tissue-specific genes

3. Binding loosens histone-DNA compaction (chromatin decondensation)

4. Target genes become more transcriptionally accessible

5. Net effect: restoration of youthful gene expression profile in aged tissue

What this means for researchers: Cartalax lacks the receptor-ligand pharmacology of most Western research peptides. Its proposed activity is transcriptional/epigenetic rather than receptor-signaling-based. Experimental design should account for this: cell-based assays examining gene expression markers (collagen II, aggrecan, Ki67) are more appropriate than receptor binding assays.

---

Cartilage Biology: The Research Context

Articular Cartilage Structure and Function

Hyaline articular cartilage is an avascular, aneural tissue covering the ends of long bones at diarthrodial joints. Its functional properties depend on a precisely organized extracellular matrix:

Collagen network:

• •Type II collagen: ~60% of dry weight; provides tensile strength and structure
• •Type XI collagen: Regulates type II fibril diameter; important for matrix organization
• •Type IX collagen: Links fibrils and proteoglycans
• •Type X collagen: Found exclusively in hypertrophic chondrocytes (mineralization zone)

Proteoglycan network:

• •Aggrecan: Large aggregating proteoglycan; binds hyaluronan; responsible for compressive resistance via fixed charge density
• •Versican, biglycan, decorin: Smaller proteoglycans with regulatory roles

Chondrocytes: The only cells in articular cartilage; ~2–5% of tissue volume; responsible for all matrix synthesis and maintenance. Chondrocytes are terminally differentiated, post-mitotic in normal adult cartilage — which contributes to the limited regenerative capacity of cartilage after injury.

Cartilage Aging and Pathology

Age-related cartilage changes are directly relevant to Cartalax's proposed research applications:

• •Reduced chondrocyte density: Cell loss due to apoptosis over decades reduces matrix maintenance capacity
• •Altered matrix composition: Age-related changes in proteoglycan size and sulfation patterns reduce compressive resilience
• •Increased oxidative stress: Chondrocyte mitochondrial ROS accumulation with age correlates with decreased viability
• •Epigenetic silencing: Methylation of promoters for COL2A1 (type II collagen) and ACAN (aggrecan) in aged chondrocytes reduces anabolic gene expression
• •MMP upregulation: Age and inflammation-associated increase in matrix metalloproteinases (MMP-1, MMP-3, MMP-13) drives ECM degradation

Osteoarthritis (OA) — the most prevalent joint disease affecting ~500 million people worldwide — represents the pathological endpoint of cartilage aging combined with mechanical, metabolic, and inflammatory stressors. No disease-modifying OA drug (DMOAD) has achieved regulatory approval as of 2026, making this a fertile research area.

---

Preclinical Research Findings

Chondrocyte Proliferation and Aging Models

The most consistently reported finding in Cartalax research is stimulation of chondrocyte proliferation in both young and aged rat models. Aged chondrocytes — which exhibit reduced replicative capacity and diminished matrix synthesis compared to juvenile cells — showed recovery of proliferation markers (including Ki67) following Cartalax exposure in Khavinson group experiments. This anti-aging cartilage biology angle is the primary driver of research interest.

Key findings from published Cartalax research:

• •Cartalax treatment in aged (24-month) rat chondrocyte cultures restored Ki67-positive proliferating cells to levels comparable to young adult controls (6-month animals)
• •The proliferation effect was dose-dependent, with optimal effects at 10–100 ng/mL concentrations
• •Effects persisted for multiple cell generations after a single Cartalax exposure, consistent with epigenetic rather than transient receptor-mediated signaling

Extracellular Matrix Markers

Research from the St. Petersburg Institute documents Cartalax effects on:

• •Collagen type II expression — the primary structural collagen of hyaline cartilage; upregulation consistent with chondrocyte anabolic activity
• •Proteoglycan synthesis — aggrecan and related proteoglycans are critical for cartilage compressive resistance; Cartalax studies report positive effects on proteoglycan production markers
• •MMP-9 modulation — matrix metalloproteinase 9 is an ECM degradation enzyme elevated in arthritic cartilage; Cartalax studies report suppression of MMP-9 in fibroblast models
• •CD98hc — a glycoprotein involved in amino acid transport and cell growth; modulation suggests effects on chondrocyte metabolic activity
• •Caspase-3 — apoptosis marker; Cartalax research reports reduced caspase-3 activity, consistent with anti-apoptotic effects in aged chondrocyte populations

Fibroblast and Skin Models

As a tripeptide matching collagen sequences, Cartalax has also been studied in skin fibroblast models relevant to cosmetic and anti-aging research. Results parallel those in chondrocytes: proliferation marker upregulation, reduced apoptosis, and ECM-supportive gene expression patterns. This cross-tissue activity is consistent with the AED sequence's presence in multiple collagen types, not just cartilage-specific type XI.

In Vivo Cartilage Studies

Several Khavinson group publications report Cartalax effects in animal OA models:

• •SC injection protocols in surgically induced OA (DMM, destabilization of medial meniscus) rats showed histological improvements in cartilage surface integrity vs. controls
• •Proteoglycan content (Safranin-O staining) was preserved to a greater degree in Cartalax-treated animals
• •These studies are limited by the absence of independent replication and Western journal publication

---

The Epigenetic Mechanism: Current Understanding

Khavinson's Proposed Mechanism

The Khavinson group has published molecular modeling studies suggesting that short peptides (2–5 amino acids) can:

1. Enter the cell nucleus via passive diffusion (molecular weight <500 Da easily transits nuclear pores)

2. Bind to specific DNA sequences through hydrogen bonding and electrostatic interactions

3. Displace histone tail contacts with DNA in target gene promoters

4. Reduce nucleosome compaction at those sites

5. Increase transcription factor accessibility

For Cartalax (AED), the proposed binding sites correspond to promoter regions of COL2A1 and ACAN genes — the key collagen and proteoglycan genes of articular cartilage.

Western Perspective: Critical Evaluation

The DNA-binding mechanism for very short peptides is considered unconventional in Western pharmacology literature for several reasons:

• •Very short peptides typically lack sufficient chemical complexity for sequence-specific DNA binding
• •In vitro DNA binding requires specific conditions and has been questioned as physiologically relevant
• •Alternative explanations — including membrane receptor interactions, cytosolic signaling pathway activation, or simple nutritive/metabolic effects — have not been conclusively excluded

However, the broader field of epigenetics has revealed increasing complexity in how small molecules can modulate chromatin — including short histone peptides that regulate each other, and emerging work on how dietary-derived short peptides (from food protein digestion) can activate specific signaling pathways in target tissues. The Khavinson mechanism is not impossible — it is simply not yet definitively proven by independent research.

Emerging Support: Peptide Epigenetics

The 2020–2026 period has seen growing interest in peptide-mediated epigenetic modulation, providing some indirect support for Khavinson's framework:

• •Lanthipeptides and other natural small peptides are known to modulate gene expression through novel mechanisms beyond classical receptor pharmacology
• •Short RGD-containing peptides modulate integrin-FAK-YAP/TAZ pathways that feed into chromatin organization
• •Tripeptide research in general has expanded, with some tripeptides showing genomic effects far out of proportion to their molecular weight

---

Comparison: Cartalax vs. Other Cartilage/Joint Research Compounds

Cartalax occupies a unique position: if its proposed mechanism is valid, it offers direct gene-level cartilage tissue modulation without receptor binding, which would be mechanistically distinct from everything else in this table.

---

Research Protocol Considerations

Cell Culture Models

• •Primary human chondrocytes: Best model for translational relevance; isolate from cartilage biopsies
• •C28/I2 cell line: Human chondrocyte-like cell line; widely used for OA research
• •ATDC5 cells: Mouse chondrogenic cell line; good for chondrogenesis studies
• •Treatment concentration: Based on published Khavinson data, 10–1,000 ng/mL range; titrate with dose-response curve
• •Treatment duration: 24–72h for gene expression studies; 7–14 days for proliferation/matrix studies

Assay Selection for Cartalax Research

Given the proposed epigenetic mechanism, appropriate assays include:

• •RT-qPCR: Measure COL2A1, ACAN, SOX9 (master chondrogenic TF) expression
• •Western blot: Collagen II protein, MMP-3/13
• •Immunofluorescence: Ki67 (proliferation), Caspase-3/7 (apoptosis), collagen II distribution
• •ELISA: Secreted collagen II propeptides, MMP activity, proteoglycan release
• •Chromatin immunoprecipitation (ChIP): If mechanistic investigation — H3K9ac, H3K4me3 at target gene promoters
• •ATAC-seq: Chromatin accessibility profiling to test epigenetic opening hypothesis

Reconstitution

• •Dissolve in sterile PBS or 0.9% NaCl
• •Working concentration: 0.1–100 µg/mL (adjust by experimental scale)
• •Stable in aqueous solution at 4°C for 1–2 weeks; freeze if longer storage needed
• •No special handling required (no D-amino acids, no disulfide bonds, no light-sensitive groups)

Storage

• •Lyophilized: -20°C, desiccated; stable ≥2 years
• •Aqueous solution: -20°C; avoid repeated freeze-thaw (>5 cycles)
• •No special container requirements

---

Cartalax Pricing: Research Supplier Landscape (2026)

Cartalax is available from multiple research peptide suppliers. As a simple tripeptide, synthesis is straightforward and prices are generally accessible:

View live pricing and verified supplier details at Peptides.SO.

What to look for in research-grade Cartalax:

• •HPLC purity ≥95% (simple tripeptides are straightforward to characterize)
• •Mass spectrometry confirmation of [M+H]+ at ~334 Da
• •Lot-specific Certificate of Analysis
• •Correct sequence (AED, not ADE or EAD): verify by amino acid sequencing if needed

---

Osteoarthritis Research Landscape: Where Cartalax Fits

The DMOAD Gap

As of 2026, no drug has been approved as a disease-modifying osteoarthritis drug (DMOAD) — one that slows cartilage loss rather than merely reducing pain symptoms. This represents a major unmet need in a disease affecting ~500 million people worldwide. The research pipeline includes:

• •Sprifermin (FGF-18): Phase 2–3 trials; showed cartilage thickness preservation on MRI, but variable functional outcomes
• •Lorecivivint: WNT pathway inhibitor; Phase 2 positive; Phase 3 mixed
• •Strontium ranelate: Approved for osteoporosis; some OA cartilage data
• •IL-1/TNF inhibitors: Effective in inflammatory OA; limited for non-inflammatory OA
• •Mesenchymal stem cell therapies: Early clinical data; promising but heterogeneous

Cartalax, if its effects on chondrocyte biology are confirmed by independent research, would represent a mechanistically distinct approach to cartilage preservation — acting at the gene expression level rather than through growth factor signaling or inflammatory pathways.

Research Opportunities

The Cartalax literature presents several specific research opportunities for investigators:

1. Independent validation: Western replication of core Khavinson findings (chondrocyte proliferation, collagen II upregulation) using orthogonal methods

2. Mechanism interrogation: ChIP-seq and ATAC-seq to test the chromatin-opening hypothesis in primary human chondrocytes

3. OA model testing: Standardized murine OA models (DMM, STR/ort) with validated histological scoring (OARSI score)

4. Combinatorial approaches: Cartalax + BPC-157, or Cartalax + hyaluronic acid, for potential synergy in cartilage matrix restoration

5. Bioavailability studies: Short tripeptide oral bioavailability and joint compartment distribution

---

Limitations and Research Considerations

Researchers approaching Cartalax should be aware of several important caveats:

Geographic research concentration: The majority of published Cartalax research originates from the Khavinson group in St. Petersburg. Independent Western replication of the reported findings is limited. This does not invalidate the research, but it means the evidence base is less externally validated than peptides with broad international study.

Mechanism debate: The proposed DNA-binding/epigenetic mechanism for short peptides of this length (<4 AA) remains unconventional by Western pharmacological standards. Alternative explanations — including non-specific mitogenic effects, receptor-mediated signaling via unknown pathways, or indirect tissue environment modulation — have not been ruled out.

Absence of clinical trial data: Unlike many GHRH analogs or GLP-1 agonists, Cartalax has no published randomized clinical trials in Western literature. Its evidence base is entirely preclinical.

Short peptide stability: AED is a tripeptide and therefore subject to rapid proteolytic degradation in biological matrices. Researchers designing in vivo or complex cell culture experiments should account for potential short half-life — stability-enhanced formulations (N-acetylation, PEGylation) may be relevant for some applications.

Effect magnitude and reproducibility: Some Khavinson bioregulator publications report effect sizes that are larger than typical for simple small peptides at nanogram concentrations. Independent dose-response characterization and blinded outcome assessment are important experimental controls.

---

Khavinson Bioregulator Research Ecosystem

Cartalax is best understood within the full Khavinson research ecosystem. Related bioregulators with parallel research programs include:

• •Epitalon (AEDG): Pineal tetrapeptide; most extensively researched Khavinson bioregulator; telomerase activation data in cell studies; aging and circadian rhythm research
• •Pinealon (EDR): Neuroprotection and cognitive aging research
• •Vesugen (KED): Vascular endothelium bioregulator
• •Vilon (KE): Thymus/immune bioregulator
• •Cortagen (AEDR): Cortex/nervous tissue bioregulator
• •Prostamax (KEDP): Prostate gland bioregulator

Researchers studying Cartalax may benefit from reading the broader Khavinson mechanism literature and comparative bioregulator studies, which provide context for interpreting Cartalax findings and evaluating the shared proposed mechanism.

---

Frequently Asked Questions

Q: What is the difference between Cartalax and other joint health research compounds like BPC-157 or TB-500?

A: They operate through fundamentally different mechanisms. BPC-157 and TB-500 work through growth factor signaling pathways (BPC-157 via EGR1/VEGFR/FAK; TB-500 via thymosin β4/actin-G:F remodeling). Cartalax's proposed mechanism is epigenetic — direct modulation of chondrocyte gene expression programs. BPC-157 has stronger animal evidence across more independent research groups. Cartalax data is primarily from the Khavinson group and specifically focused on cartilage/chondrocytes.

Q: Can Cartalax be used alongside other connective tissue peptides?

A: No contraindications are documented in preclinical literature. Combinatorial research with BPC-157, hyaluronic acid, or other cartilage-support compounds is a logical research direction. No interaction data exists.

Q: What dose range is used in research?

A: Based on published Khavinson protocols, typical in vitro concentrations are 10–1,000 ng/mL in cell culture medium. In vivo rodent doses are approximately 2–10 µg/kg/day via SC or IP injection. There is no established human dose as no clinical trials have been published.

Q: Is Cartalax related to Epitalon? They share two amino acids (A and E)?

A: They share structural similarities — both are short Khavinson bioregulators with overlapping amino acid compositions. Epitalon (AEDG) contains Ala-Glu-Asp-Gly; Cartalax (AED) is identical except it lacks the terminal Gly. The research programs suggest different tissue targets (pineal/telomerase for Epitalon vs. cartilage/chondrocytes for Cartalax), though the AED sequence could be considered the core of both peptides.

Q: How does Cartalax compare to glucosamine and chondroitin?

A: Glucosamine and chondroitin sulfate work as biosynthetic substrates and mild anti-inflammatory agents via NF-κB pathway modulation. They provide building blocks for proteoglycan synthesis but don't directly modulate gene expression. Cartalax's proposed epigenetic mechanism acts at a more fundamental level — if validated, it would theoretically target the root cause of chondrocyte dysfunction rather than providing substrate. However, glucosamine/chondroitin have substantial human clinical data (though mixed for efficacy) while Cartalax has none.

---

Related Research Articles

• •TB-500 (Thymosin Beta-4) Research Guide 2026
• •BPC-157 vs TB-500: Which Healing Peptide Is Better for Research?
• •Peptide Purity Testing Methods: HPLC and Mass Spectrometry Explained
• •Prostamax (KEDP Tetrapeptide): Complete Research Profile

---

Conclusion

Cartalax occupies a distinctive niche in the peptide research landscape as the cartilage-specific member of the Khavinson bioregulator family. Its proposed mechanism — epigenetic modulation of chondrocyte gene expression through direct DNA binding — is mechanistically unconventional but increasingly contextualized by the broader field of peptide-mediated epigenetic research.

The preclinical data from the Khavinson group consistently shows chondrocyte proliferation stimulation, collagen II and proteoglycan upregulation, MMP-9 suppression, and anti-apoptotic effects in aged cartilage models. These effects, if independently validated, would make Cartalax a valuable research tool for cartilage aging biology and potentially a candidate for DMOAD development.

For Western researchers, Cartalax represents both a scientific curiosity and a genuine research opportunity: independent validation of the reported effects using modern molecular tools (RNA-seq, ChIP-seq, ATAC-seq) would either confirm the Khavinson findings and establish an important new mechanism, or clarify the actual biology underlying whatever effects are observed.

In the context of the unmet clinical need for disease-modifying OA therapy, any mechanism that can restore anabolic activity to aged chondrocytes deserves systematic investigation.

Research Use Only. Cartalax is sold for research purposes only. Not for human consumption. Consult applicable regulations before use.